IndustryCompany release

Senti Biosciences divests operating subsidiaries in merger, retaining only Rett Syndrome and TIL programmes

🇺🇸 Senti Biosciences Holdings, Inc. (SNTI) · Mon 26 Oct 2026

Pro forma financials for a merger agreed on 14 July 2026 show Senti Biosciences Holdings with about $3.1 million in cash after handing its operating units to ST NewCo Limited.

Senti Biosciences Holdings, Inc. has filed pro forma financial information for a merger agreement dated 14 July 2026. Under the transaction, the company divested its Midco and Opco subsidiaries to ST NewCo Limited, the entity formerly known as Celadon Partners SPV 35 Limited.

Senti retains the licensed or assigned intellectual property and contracts it needs to advance its Rett Syndrome and TIL programmes. It will also receive transitional support from Opco. The summary on file does not describe the scope, duration or terms of that support.

The pro forma balance sheet shows cash of about $3.1 million and total assets of about $3.2 million. The material available does not give the consideration, any liabilities, or a development timetable for the two retained programmes.

The source text of the filing was not available to VigiEye, so this report rests on the summary of the filing only.

What it means for your team

  • Partners and service providers linked to Senti's former operating units should check which contracts moved to ST NewCo Limited and which stayed with Senti.
  • Regulatory and quality teams working with the Rett Syndrome and TIL programmes should confirm who holds the relevant IP and who provides transitional support from Opco.
  • With cash of about $3.1 million on the pro forma balance sheet, the programmes' funding and timelines are not addressed in the available material and warrant follow-up from the full filing.

Company's press release (SEC filing): Senti Biosciences Holdings, Inc. ↗

Article written by VigiEye from the official source (Senti Biosciences Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →